From the Center for Environmental and Rural Health, Texas A & M University, College Station, Texas 77843-4455
Received for publication, April 14, 2003
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Monomers function as promoters, with increases in promoter activity as the number of monomers increase (10). Regardless of the number of monomers in an individual A- or F-type L1Md, monomers always contain two-thirds of full-length monomer at their most 5' end tandem repeat, although their specific role in gene activation is unknown. Three A-type subfamily members have been described, L1Md-A2 with 4 and 2/3, L1Md-A13 with 2 and 2/3, and L1Md-9 with 1 and 2/3 copies of monomers (4, 11). The structure of L1 in the mammalian genome may be represented by the well characterized L1Md-A2, which consists of six to seven kb including a 5' untranslated region (UTR), two open reading frames (ORFs) (1137-bp ORF1 encoding ribonucleoprotein (12, 13) and 3900-bp ORF2 encoding endonuclease and reverse transcriptase (14, 15)), a 3' UTR, and a 3' end poly(A) tail. A few bp target direct repeats are always found before and after the 5' UTR and 3' UTR, respectively, a feature consistent with active transposition into new locations. The regulation and subsequent expression of L1 elements remains among the most critical unanswered questions concerning the structure and genomic organization of L1.
Factors known to activate retrotransposons include radiation (16, 17), chemical carcinogens (18, 19), and stress-related factors (20, 21). Retrotransposon activation may play a role in evolution of the genome (22), double strand break DNA repair (23), exon shuffling (24, 25), and diseases caused by insertional mutation in both human (2629) and mice (3034). A recent report (35) describing transcriptional interference by somatically active retrotransposons as epigenetic mediators of phenotypic variance among mammals raises important questions about their impact in development and progression of human disease. Previous studies in this laboratory (18) have shown that benzo(a)pyrene (BaP), a polycyclic aromatic hydrocarbon carcinogen and atherogen, activates L1Md expression in mouse vascular smooth muscle cells. L1Md activation is also elicited by oxidative metabolites of the parent hydrocarbon, suggesting that modulation of redox homeostasis mediates epigenetic disruption of gene expression and possibly DNA damage (19).
Here we identify for the first time a novel A-type L1Md in mouse vascular smooth muscle cells that contains 3 and 2/3 copies of A-monomers within the 5' regulatory region. PCR analysis of genomic DNA showed tissue-specific distribution of the gene, with strong amplification signals detected in vascular smooth muscle cells, and to a lesser extent mammary gland and kidney. Sequence alignment to L1Md-A2 indicated that a full-length monomer equivalent (the entire 140-bp incomplete monomer A2/3 and the 68 bp from adjacent first full monomer A4) is absent in the most 5' end tandem repeat of the regulatory region. This element, named L1Md-A3.6, preserved its promoter activity and was inducible by carcinogenic environmental hydrocarbons via a redox-sensitive mechanism involving ARE/EpRE-like sequences. Site-directed mutagenesis and progressive deletion analyses showed that: 1) promoter activity increases as the number of monomers increase, 2) the A2/3 monomer in genomic context may inhibit gene expression, 3) A1 alone lacks promoter activity but may assist in monomer-driven transactivation, 4) mutation of both ARE/EpRE-like sites within A2/3 and A3 markedly reduce inducible activity, and 5) mutation at A3 alone significantly reduced BaP inducibility. Collectively, these data suggest that oxidative stress plays a significant role in the activation of a novel member of the A-type L1Md subfamily in vascular smooth muscle cells.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Polymerase Chain ReactionThree sets of primers were designed using oligo 4.0 (National Biosciences) based on the published L1Md-A2 sequence. Region 1 primer set (forward, 5'-CCCAACATAGAGTCCTGA-3'; reverse, 5'-AGTGGGCAGAGTATTCTC-3') was designed to generate a 1114-bp PCR product from nucleotide (nt) 515 to 1628 of L1Md-A2 and spanning the complete four and 2/3 A-monomers. Region 2 primer set (forward, 5'-GCCCTTCTGGACTTATCTCTTC-3'; reverse, 5'-TTGCGGGTGTCAGGCGACTCAG-3') was used to generate a 1008-bp fragment from nt 477 to 1484 of L1Md-A2 covering 3 and 2/3 A-monomers. Region 3 primer set (forward, 5'-TGCCCACTTTCTCCCTACCT-3'; reverse, 5'-GCTTTTCCCCACTTTCTCCTC-3') was designed to generate a 972-bp fragment from nt 4856 to 5827 of L1Md-A2 ORF2 region. Each PCR reaction contained the following: 20 µM dNTPs, 200 pmol of each primer, 0.02 units/µlof Taq DNA polymerase (PerkinElmer Life Sciences), 1x MgCl2 containing PCR buffer, and various amounts (8001 ng) of genomic DNA. Amplification reactions were performed for 25 cycles, and each cycle consisted of a 30-s denaturation at 94 °C, 1-min annealing at 60 °C, and 2-min extension at 68 °C. For analyses of tissue distribution, 1 mg of genomic DNA was amplified in a 50-ml reaction containing 200 µM dNTPs, 500 pmol of primer (upper primer, 5'-AAAAAGCTTCCCAACATAGAGTCCTGA-3'; lower primer, 5'-AAAAAGCTTAGTGGGCAGAGTATTCTC-3'), 0.025 units/µl AmpliTaq Gold DNA polymerase (PerkinElmer Life Sciences), and 1x MgCl2 containing PCR buffer. Amplification reactions were performed for 30 cycles, and each cycle consisted of a 45-s denaturation at 95 °C, 1-min annealing at 60 °C, and 1-min, 15-s extensions at 68 °C following initial denaturation at 95 °C for 5 min.
Plasmid Construction and SequencingpGB3.611 containing a full-length 5' tandem repeat (designed to generate nt 5151628 of L1Md-A2) was constructed by first cloning the PCR product generated from the HindIII restriction site attached to the 5' end of Region 1 primer set M13002 [GenBank] 18H (forward, 5'-AAAAGCTTGCCCTTCTGGACTTATCTCTTC-3'; reverse, 5'-AAAAGCTTTTGCGGGTGTCAGGCGACTCAG-3') into HindIII digested blunt end linearized PCR-TRAP vector (GenHunter Corp., Nashville, TN). After a successful clone was confirmed by a colony-PCR method using a primer set that flanks the cloning site of the PCR-TRAP vector, the insert fragment was retrieved by digestion of the plasmid with HindIII restriction enzyme and subcloned into pGL3 basis luciferase reporter vector (Promega). All plasmids with correct inserts were confirmed by sequencing from both ends to ensure that the correct sequence was cloned.
Transient Transfection AssayMouse vascular smooth muscle
cells were seeded at 1 x 105 cells in 12-well plates and
maintained at 37 °C (5% CO2) in Medium 199 supplemented with
10% fetal calf serum. After seeding for 24 h, cells were transfected with
pGB3.611 or pGB3.68, plasmids containing the
sense or antisense strand of Region 1 product, respectively, or mutant
plasmids, for 2 h. Briefly, 2 µg of plasmid DNA and 0.5 µg of
-galactosidase (pcDNA/His/lacz) were mixed with 400 µl of
serum-deprived OPTIMEM-1 medium. Then, 7.5 µl of TransFast transfection
reagent (Promega) was added, vortexed immediately, and incubated at room
temperature for 15 min. Growth medium was carefully removed, and 400 µl of
TransFast reagent (Promega)/DNA mixture added to each well. Plates were
returned to the incubator for 2 h. At the end of the incubation, transfected
cells were recovered in 1 ml of Medium 199 supplemented with 10% serum for 24
h followed by challenge with BaP (0.3, 3, 30 µM), TCDD (0.1, 1,
10 nM), or H2O2 (25, 50, 100
µM) for 24 h. For antioxidant inhibition studies, cells were
pre-treated with 0.5 mM N-acetylcysteine or 0.01
µM PDTC for 3 or 6 h, respectively, before challenge with
carcinogens. To harvest the cells, transfected cells were washed twice with
phosphate-buffered saline, lysed in 175 µl of 1x reporter lysis
buffer, and collected into a microtube. The suspension was then incubated at
room temperature for 15 min followed by one cycle of quick freeze-thaw in
liquid nitrogen and water at room temperature. The resulting cell lysate were
collected after centrifugation at 12,000 x g for 1 min. For
measurements of luciferase activity, 30 µl of cell lysate was mixed with
100 µl of luciferase assay reagent (Promega) in a 96-well plate and read at
420 mm in a plate reader. For
-galactosidase activity, 30 µl of cells
lysate was mixed with 70 µl of substrate and incubated at room temperature
for 5 min followed by addition of 100 µl of accelerate II buffer (Promega)
and read in a plate reader.
Site-directed Mutagenesis and Deletion AnalysisSite-directed mutagenesis was performed using a GeneEditor in vitro site-directed mutagenesis system (Promega) according to manufacturer's specifications. Briefly, a 4-bp (boldface in the mutagenesis oligo) mutation was designed to generate mutations within the ARE/EpRE-like consensus sequence 5'-GTGACNNNAGC-3' of pGB3.611 using the mutagenesis oligo 5'-CCTTCCGCTCGACTCTGCAGTCGAGCCCCGGGCTA-3'. PstI and XhoI restriction sites were engineered to facilitate screening of successful mutant clones. As a result, pMut-12 plasmid containing both ARE/EpRE mutations, one each within A2/3 and A3, respectively, was generated. pMut-4 plasmid contains an additional nonspecific mutation within A2 because of high sequence similarity among monomers. For deletion analyses, pWtA2/3 and pWtA321 plasmids were first recovered from pGB3.611 by HindIII digestion followed by SacII digestion to separate the A2/3 region from the A3, 2, and 1 monomers. A2/3 and A321 fragments were then blunt end cloned into HindIII digested pGL3 basic luciferase reporter vectors to give the pWtA2/3 and pWtA321 plasmids, respectively. Deletion plasmids pMutA2/3 and pMutA321 were generated from pMut-12 using the same strategy. HindII/SacII digested A321 fragment from pGB3.611 was then used as PCR template for pA32, pA21, and pA1. The deletion construct pA32 was generated using upper primer 5'-AAAAAGCTTGTGCCTGCCCCAAT CCAATCGCGCGG-3' and lower primer 5'-AAAAAGCTTTGTGTTCCACTCAC CAGAGGTCTTAG-3'. Deletion plasmids pA21 and pA1 were generated from lower primer 5'-AAAAAGCTTTGTGTTCCACTCACTAGAGGTCTTAG-3' in conjunction with upper primers 5'-AAAAAGCTTGTGCCTGCCCCAATCCAATCGCGCGG-3' and 5'-AAAAAGCTTGCGCCTACCCCAATCCAATCGCGTGG-3', respectively. All mutations and deletions were confirmed by DNA sequencing prior to transfection.
Real-time RT-PCRTotal RNA was extracted using TRI reagent (Molecular Research Center, Inc.) from serum-stimulated mouse vascular smooth muscle cells treated with 3 µM BaP or an equivalent volume of Me2SO for 8 h following growth arrest in 0.1% serum containing medium 199 for 48 h. Primers were designed using Primer Express Software (PerkinElmer Life Sciences). Location and sequences of primers were as follows: 5' UTR (nt 307 to 383 of L1Md-A2) forward, 5'-ATTGAAGAGGGACAGAAAAACAAAG-3' and reverse, 5'-ACTGTGGTCAGGGCACAAATG-3'; ORF2 (nt 5896 to 5999 of L1Md-A2) forward, 5'-AATCGACAAATGGGACCTAATGA-3' and reverse, 5'-GTAAAGATCCTTTCCCAATCTGTTG-3'; internal control gene 18S (nt 1679 to 1748 of GenBankTM accession number X00686 [GenBank] ) forward, 5'-AGTCCCTGCCCTTTGTACACA-3' and reverse, 5'-CGATCCGAGGGCCTCACTA-3'. Real-time RT-PCR was performed using the ABI-PRISM 7700 sequence detection system (PerkinElmer Life Sciences). Two µg of genomic DNA was first reverse-transcribed to cDNA using TaqMan reverse transcription reagents (PerkinElmer Life Sciences) in a reaction volume of 100 µl containing 1x TaqMan RT buffer, 5.5 mM MgCl2, 500 µM each dNTP, 2.5 µM reverse primers, 0.4 units of RNase inhibitor, and 1.25 units of MultiScribe reverse transcriptase under conditions of 25 °C for 10 min, 48 °C for 30 min, followed by 95 °C for 5 min in a thermocycler. Five µl of cDNA was then amplified in a total volume of 50 µl, containing 1x SYBR Green PCR Master Mix and 2.5 to 45 µM reverse and forward primer at 95 °C for 10 min followed by 40 cycles of 15-s denaturing at 95 °C and 1 min annealing at 95 °C in the ABI-PRISM 7700. All reactions were performed in triplicate.
Sequence AlignmentSequences were aligned, and consensus sequences were determined using MacVector 7.0 (Oxford Molecular Group).
Accession NumberThe L1Md-A2 GenBankTM accession number is M13002 [GenBank] , and for L1Md-A3.6 it is AF502598 [GenBank] .
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
|
BaP-induced L1Md-A3.6 ActivationReal-time RT-PCR is a high throughput technology that allows rapid and sensitive detection of gene expression (36, 37). Because families of retrotransposons are known to be conserved at the 3' end and differ at their 5' untranslated region (38), it was hypothesized that the newly identified L1Md-A3.6 evolved from L1Md-A2. Therefore, real-time RT-PCR was performed to evaluate inducibility of L1Md-A3.6 in response to BaP activation of ORF2 in L1Md-A2. A region containing DNA sequence upstream of monomers was used as control. The normalized amount of ORF2 for each treatment was determined by dividing the expression values for each treatment by the amount of corresponding endogenous reference 18S. The average of triplicate BaP-treated cultures was divided by the control average to give the relative amount of ORF2 in BaP-treated over Me2SO control cells. The amplification profiles for both ORF2 and 18S, and the summary of -fold induction of the gene is shown in Fig. 3 and Fig. 4, a and b, respectively. As expected, no amplification was detected for the 5' end tandem repeat promoter sequence (Fig. 4b). In contrast, BaP treatment significantly increased expression of L1Md-A2 ORF2 region, confirming that L1Md-A3.6 is a member of the L1Md-A2 family with one monomer short in its 5' tandem repeat region.
|
|
Inducibility of L1Md-A3.6 The mechanism of retrotransposon activation is unknown. To understand the regulation of retrotransposon activation in vascular smooth muscle cells by carcinogen treatment and to determine whether L1Md promoter activity is intact regardless of monomer shortening in the 5' tandem repeat, L1Md-A3.6 was subcloned into a luciferase reporter vector pGL3 basic vector and used in transient transfection assays. Fig. 5a shows the luciferase reporter activity of L1Md-A3.6 in mouse vascular smooth muscle cells. L1Md-A3.6 preserved its promoter function, such that luciferase activity was detected in both pGB3.68 and pGB3.611, plasmids containing the L1Md-A3.6 sequence in reverse and correct orientation, respectively. The promoter activity in pGB3.68, although considerably reduced, is consistent with a report showing that the retrotransposon promoter in antisense orientation is capable of disrupting neighboring genes (38). To further evaluate the inducibility of L1Md-A3.6, pGB3.611 transfected cells were challenged with 0.3, 3, and 30 µM BaP or an equivalent volume of Me2SO as vehicle control for 24 h. As shown in Fig. 5b, BaP treatment increased luciferase activity in a concentration-dependent manner relative to Me2SO controls. When transfected cells were pre-treated for 3 h with N-acetylcysteine, an antioxidant precursor of cellular glutathione, marked inhibition of BaP-induced gene transcription was observed. Thus, an oxidative mechanism may mediate activation of the gene by the carcinogen. To test this hypothesis, the inhibitory effects of the antioxidant PDTC were examined. Pre-treatment of vascular smooth muscle cells with PDTC for 6 h also prevented activation of the gene (Fig. 5b). Oxidative stress is associated with retrotransposon activation in plants (20); however, to our knowledge, this is the first report showing redox-dependent activation of retrotransposons in mammalian cells.
|
To determine whether other carcinogenic hydrocarbons known to induce oxidative stress modulate L1Md transactivation profiles, the effects of TCDD (0.110 nM) were examined. Like BaP, TCDD induced concentration-dependent activation of the luciferase reporter, and this effect was antagonized by N-acetylcysteine (Fig. 5c). The response appears to be specific for carcinogenic hydrocarbons, because hydrogen peroxide (25100 µM), a known inducer of oxidative stress, failed to induce L1Md-A3.6 activation (Fig. 5d). Hydrogen peroxide was highly cytotoxic to vascular smooth muscle cells at higher concentrations, so higher peroxide concentrations could not be tested.
Role of ARE/EpRE in L1Md-A3.6 ActivationOverproduction of free radicals via cycles of reduction and oxidation between phenolic and quinone metabolites of BaP induces oxidative stress and plays a critical role in dysregulation of vascular smooth muscle cells (39). A DNA sequence known as the ARE/EpRE (antioxidant/electrophile responsive element) mediates transcriptional activation of several genes, such as GSTA1 (40) and NAD(P)H:quinone oxidoreductase 1 (41). This element (5'-GTGACNNNGC-3') is responsive to BaP in vascular smooth muscle cells (40) and therefore, may mediate transcriptional regulation of L1Md-A3.6. To test this hypothesis, we introduced a 4-bp mutation within the two ARE/EpRE-like sites (5'-GTGACNNNAGC-3'), one each within the A2/3 and A3 monomers of L1Md-A3.6, respectively. Mutation of G to T, T to G, G to C, and C to G were created within the ARE/EpRE-like sequence from the 5' to 3' end, respectively (Fig. 6a). pMut-12 contains two perfect ARE/EpRE mutations, one each within A2/3 and A3 monomer, whereas pMut-4 contains an additional nonspecific ARE/EpRE mutation within A2 monomer. Transient transfection of these mutants into vascular smooth muscle cells showed that the promoter activity of L1Md-A3.6 was markedly inhibited by mutation of both A2/3 and A3 ARE/EpRE sites compared with wild type. Under both basal and inducible conditions, nonspecific mutation of A2 did not alter the inducibility of L1Md-A3.6 promoter activity, suggesting that the ARE/EpRE-like elements play a critical role in activation of the gene.
|
In agreement with previous studies (10), the promoter activity of L1Md-A3.6 increased as the number of monomers increases (compare pA1, pA21, and pWtA321). However, in vascular smooth muscle cells, this pattern only applied when the A2/3 monomer of L1Md-A3.6 was removed from the full-length construct, as evidenced by significant differences in luciferase activity between pWt321 and pA21, or the full-length wild type plasmid. Thus, inhibitory sequences may reside within the 62171-bp region of A2/3, an interpretation consistent with the finding that partial A2/3 deletion mutants were more active under constitutive conditions than wild type counterparts. Comparison of pWtA321 and pMutA321 showed that BaP inducible activity in pGB3.611 is mediated by the ARE located within the A3 monomer. Monomer interactions are important for the regulation of L1Md-A3.6 given that pA1 completely lost promoter activity, whereas the pA32 deletion construct containing a functional ARE showed markedly reduced activity compared with wild type. pWtA2/3 was only modestly active, a pattern not influenced by mutational ablation of the ARE. Thus, site-directed mutagenesis and deletion analyses indicate that interactions between ARE/EpRE-like elements are involved in both basal and inducible activation of L1Md-A3.6, with the A3 monomer functioning as the major driving force for transcriptional activation of the gene.
Putative Model of L1Md-A3.6 RegulationTo gain further
insight into functional differences between the ARE/EpRE-like sites within
A2/3 and A3 monomers, the sequences of L1Md-A3.6 were further
evaluated. Fig. 7 shows the
sequence alignment among monomers of L1Md-A3.6. Four base pairs at
position 1, 82, 97, and 107 of A2/3 differed from corresponding nucleotides at
69, 150, 165, and 175 of A3. Monomer sequences encompassing nt 1120 of
A2/3 and the corresponding sequence on A3 were then submitted for
transcriptional factor binding site analysis at
www.cbrc.jp/research/db/TFSEARCH.html.
The most significant finding was that a change of A to G at position 107 of
A2/3 creates a Ttk 69 binding site. Ttk 69 is a binding site for a repressor
protein Tramtrack69, which plays a role in asymmetric cell division during
Drosophila eye development
(42,
43) and may be involved in ARE
signaling (44). Also
noteworthy was the finding that changing of G to A at position 97 and A to G
at position 107 in A2/3 disrupted NF-B and USF binding sites,
respectively, within A3.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Retrotransposons are mobile DNA elements that propagate through transcription and reverse transcription and reintegration into new locations within the genome. Two major types of retrotransposons have been described, one containing LTRs that resemble retroviral pro-viruses versus non-LTRs having no terminal repeats but poly(A) tails (45). LTRs function as retroviruses and use reverse transcriptase and integrase encoded by pol-like open reading frame for their transposition. Non-LTRs were originally discovered in mammalian genomes (2) but have now been detected in a wide range of species from protozoa to fungi, plants, and animals. Non-LTRs usually contain two ORFs. ORF1, near the 5' end of the element, encodes nucleic acid-binding proteins that form ribonucleoprotein particles during transposition (46), whereas ORF2 encodes for reverse transcriptase and endonuclease (47). In mammals, a major class of non-LTR retrotransposons consists of the highly repetitive LINEs (long interspersed repetitive elements), including the L1 family, the mouse-specific L1Md family, and the chicken-specific CR1 family (48). Insertion into chromosomal DNA probably occurs by a process termed target-primed reversed transcription; the endonuclease of ORF2 nicks a single strand of DNA, leaving a 3'-OH that serves as the primer for reverse transcription with the L1 RNA as template (49).
L1Md-A3.6 preserved its promoter function and was inducible by aromatic hydrocarbons that activate aryl hydrocarbon receptor (Ahr) signaling. Ahr is a ligand-activated transcription factor member of the basic helix-loop-helix family of transcription factors. Activation of Ahr signaling disrupts programs of gene expression and phenotypic control in vascular smooth muscle cells (39). Interestingly, L1Md-A3.6 induction by aromatic hydrocarbons was abolished by two antioxidants, N-acetylcysteine and PDTC, a finding that suggests that oxidative mechanisms play a central role in regulation of the gene. Oxidative stress is associated with retrotransposon activation in plants (20), but to our knowledge this is the first report showing redox-dependent activation of retrotransposons in mammalian cells. The role of oxidative mechanisms in retrotransposon activation is complex, because peroxide treatment, a vascular smooth muscle cell oxidant, failed to transactivate the L1Md-A3.6 promoter. Instead, the observed pattern of redox-dependent regulation is consistent with the ability of BaP and TCDD to activate functional cross-talk between ARE-binding proteins and Ahr in the regulation of mammalian gene expression (40, 50). Of note is the finding that hydrogen peroxide does not activate Ahr signaling in vascular smooth muscle cells (50).
ARE-binding proteins are redox-regulated transcription factors of the basic leucine zipper superfamily that "sense" alterations in cellular redox balance following environmental stress (44). Over production of free radicals via cycles of reduction and oxidation between phenolic and quinone intermediates in BaP-treated cells induces oxidative stress and activates ARE signaling in vascular smooth muscle cells (51). As shown for other BaP-responsive genes, AREs mediate transcriptional regulation of L1Md-A3.6. Mutation of two ARE/EpRE-like sites (5'-GTGACNNNAGC-3'), one each within the A2/3 and A3 monomers of L1Md-A3.6, respectively, markedly inhibited promoter activity. Hydrocarbon-inducible activity, however, was dependent upon the ARE sequence located within A3. Functional differences between the A2/3 and A3 AREs may be accounted for by genomic context-specific characteristics of protein binding and complex assembly. Together, the data presented here provide strong experimental support for the hypothesis that the A3 ARE/EpRE-like element plays a critical role in gene activation, particularly within the context of hydrocarbon inducibility.
Sequence analysis of L1Md-A3.6 sequences identified several
putative redox-regulated cis-acting elements, including c-Ets,
NF-B, USF, and Ttk 69, within the A2/3 and A3 monomers. Thus,
interactions between proteins that recognize these sequences may dictate
patterns of L1Md-A3.6 transactivation and repression throughout the
mouse genome. This interpretation is consistent with the ability of BTB
proteins, such as Tramtrack69, to interact with nrf2 and other
Cap'N'Collar proteins in the regulation of ARE/EpRE-coupled
transcription (44). Such
protein-protein interactions may define critical regions within A2/3 and A3
that are regulated by environmental carcinogens that activate Ahr.
Propagation and integration of LINEs is believed to play a major role in the pathogenesis of several human diseases, including hemophilia (52), colon cancer (53), and breast cancer (54). Alkylating esters of methanesulfonic acid (55), mitomycin C (56), and azacytidine (57) have all been shown to induce retrotransposition. Recent evidence has established an association between L1 retrotransposition and genomic instability as evidenced by element inversions, extra nucleotide insertions, exon deletions, chromosomal inversion, and flanking sequence co-mobilization (58, 59). Thus, epigenetic mechanisms involving L1Md-A3.6 activation in vascular smooth muscle cells may give rise to genomic instability and vascular injury following environmental exposure to chemical carcinogens. This hypothesis is consistent with the ability of environmental hydrocarbon carcinogens to induce atherosclerotic lesions in laboratory animals and humans (for a review see Ref. 39). The distribution patterns of L1Md-A3.6 suggest that genetic consequences resulting from activation of L1Md-A3.6 transposon may be a generalized response in several mouse tissues.
In summary, evidence is presented here that environmental carcinogens activate a novel gene of L1Md-A2 lineage in vascular smooth muscle cells. Gene regulation is mediated via a redox-sensitive mechanism involving monomer-regulated transcription by two ARE-like elements within the A2/3 and A3 region. The full monomer equivalent truncation model described here for L1Md-A3.6 implicates monomer as a mechanism for molecular evolution of L1Md-A-type retrotransposons that either preserve or lose functional full-length retrotransposon activity, respectively.
![]() |
FOOTNOTES |
---|
To whom correspondence should be addressed: Dept. of Biochemistry and
Molecular Biology and Center for Genetics and Molecular Medicine, University
of Louisville Health Sciences Center, Louisville, KY 40292. Tel.:
502-852-5217; Fax: 502-852-6222; E-mail:
kenneth.ramos{at}louisville.edu.
1 The abbreviations used are: LTR, long terminal repeat; UTR, untranslated
region; ORF, open reading frame; BaP, benzo(a)pyrene; nt, nucleotide; TCDD,
2,3,7,8-tetrachlorodibenzo-p-dioxin; PDTC, pyrrolidine
dithiocarbamate; RT, reverse transcriptase; Ahr, aryl hydrocarbon
receptor.
![]() |
ACKNOWLEDGMENTS |
---|
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|